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Asialoglycoprotein receptor (ASGPR)-mediated endocytosis has been used to target genes to
hepatocytes in vivo. However, the level and duration of transgene expression have been low
because of lysosomal translocation and degradation of the DNA and lack of its integration into
the host genome. In this study we packaged the DNA of interest in proteoliposomes containing
the fusogenic galactose-terminated F-glycoprotein of the Sendai virus (FPL) for targeted delivery
to hepatocytes. After the FPLbinds toASGPRon the hepatocyte surface, fusogenic activity of the
F-protein delivers the DNA into the cytosol, bypassing the endosomal pathway. For transgene
integration we designed plasmids containing one transcription unit expressing the Sleeping
Beauty transposase (SB) and another expressing human uridinediphosphoglucuronate glucu-
ronosyltransferase-1A1 (pSB-hUGT1A1). The latter was flanked by inverted/direct repeats that
are substrates of SB. In cell culture, FPL-mediated delivery of the E. coli -galactosidase gene
(LacZ) resulted in transduction of ASGPR-positive cells (rat hepatocytes or Hepa1 cell line), but
not of ASGPR-negative 293 cells. Intravenous injection of the FPL-entrapped pSB-hUGT1A1
(4-8g/day, 1-4doses) intoUGT1A1-deficienthyperbilirubinemicGunn rats (model ofCrigler-
Najjar syndrome type 1) resulted in hUGT1A1 expression in 5%-10%of hepatocytes, but not in
other cell types. Serum bilirubin levels declined by 30% 4% in 2 weeks and remained at that
level throughout the 7-month study duration. With histidine containing FPL, serum bilirubin
was reduced by 40% 5%, and bilirubin glucuronides were excreted into bile. No antibodies
were detectable in the recipient rats against the F-protein or human UGT1A1. Conclusion: FPL
is an efficient hepatocyte-targeted gene delivery platform in vivo that warrants further explora-
tion toward clinical application. (HEPATOLOGY 2009;50:815-824.)
Although recombinant viruses have been used ex-tensively in gene therapy, nonviral vectors forgene transfer are of great interest because of a
lower potential for toxic or immunological reactions. One
benefit of nonviral vectors is the possibility of delivering
genes to specific cell types. Targeted delivery to hepato-
cytes could provide some important benefits for the treat-
ment of liver-based disorders. Rapid and efficient
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clearance of the therapeutic agent would reduce the re-
quired dose and spare other tissues of potential toxicity.
Reduced exposure of potential antigens to antigen-pre-
senting cells may abrogate the immune response to the
gene/drug transfer vehicle and the transgene product.
Antibodies against cell surface proteins or ligands of
cell surface receptors are being explored for endocytosis-
based delivery of macromolecules to normal or tumor
cells. For example, nucleic acids complexed with asialo-
glycoprotein-polylysine conjugates1,2 or incorporated
into galactocerebroside-containing liposomes3 have been
used to deliver DNA to hepatocytes in vivo by way of the
hepatocyte-specific asialoglycoprotein receptor (ASGPR).
However, transgenes delivered by way of endocytosis are
typically translocated to lysosomes, where they largely de-
graded by lysosomal enzymes. Interruption of this traf-
ficking to lysosomes by disrupting microtubules prolongs
transgene expression,4 but because the DNA is compart-
mentalized into cytoplasmic vesicles, transgene expression
remains low.5 To take advantage of the hepatocyte-spec-
ificity of ASGPR, while circumventing lysosomal translo-
cation, investigators have utilized the naturally galactose-
terminated fusogenic F-glycoprotein of the Sendai virus
envelope.6,7 In the presence of hemagglutinin/neuramin-
idase (HN), another major protein of the Sendai virus
envelope, F-protein binds to cell surface membranes
ubiquitously, causing fusion.8 Vectors containing both
HN and F proteins can deliver macromolecules to all cell
types and, when injected intravenously, localize primarily
to the spleen.8 Thus, these vectors are not desirable for
liver-targeted gene transfer in vivo. In contrast, when HN
is removed, F-protein binding requires interaction of its
galactose-terminated carbohydrate moieties with AS-
GPR.6 Therefore, liposomes containing the F-protein,
but not HN, bind specifically to hepatocytes. After the
proteoliposome binds to hepatocyte surface ASGPR, fu-
sogenic activity of the F-protein leads to deposition of its
contents into the hepatocyte cytosol, bypassing the endo-
cytotic pathway, and thereby enhancing DNA transloca-
tion to the nucleus.6
Here, we evaluated the utility of F-protein-containing
proteoliposomes (FPL) in gene therapy for a hepatocyte-
based inherited liver disease. TheGunn rat, amodel of the
potentially lethal human disease Crigler-Najjar syndrome
type 1,9 exhibits life-long unconjugated hyperbiliru-
binemia because of the lack of uridinediphosphoglucur-
onate glucuronosyltransferase 1A1 (UGT1A1) activity in
hepatocytes. To obtain a long-term effect, we used the
Sleeping Beauty (SB) transposon system, which promotes
transposition of the transgene into the host genome.10 We
also tested the hypothesis that rapid clearance of FPL by
hepatocytes would prevent the exposure of the F-protein
to the host immune system, thereby obviating the im-
mune response against the vector.
Materials and Methods
Animals. (Details of theMaterials andMethods are in
the Supporting Material.) Gunn rats of both genders (80-
100 g initial body weight) were used.
Plasmid Constructs. Three plasmid constructs were
used: (1) pT2-pCAAGS-hUGT1A1//eIF-SB10 (Fig. 1)
contains two transcription units, one expressing a hyper-
active Sleeping Beauty transposase (a gift from Dr. Steve
Yant)11 driven by the eIF4A1 promoter. A second tran-
scription unit, flanked by the Sleeping Beauty inverted
repeat/direct repeats (IR/DR) expressed human
UGT1A1 (hUGT1A1) from a CAGGS promoter. As
marker genes, we generated plasmid (2) pT2-pCAAGS-
LacZ//eIF-SB10, expressing E. coli -galactosidase and
(3) pT2-pCAAGS-Luc//eIF-SB10, expressing firefly lu-
ciferase by replacing the human UGT1A1 sequence with
the LacZ or firefly luciferase sequences, respectively.
Generation of DNA-Loaded FPL.12 Sendai virus,
grown in chicken embryo, was harvested by centrifuga-
tion of the allantoic fluid. The disulfide bonds were re-
duced by treatment with dithiothreitol (DTT), whichwas
then removed by dialysis, thereby renaturalizing the F-
protein, but not other viral proteins. The F-protein was
solubilized in Triton X-100 and the DNA of interest was
added. The DNA was entrapped into FPL by removing
Triton X-100, using SM2 Biobeads (BioRad). In some
experiments, to enhance the fusogenic activity of the FPL,
histidine lipids (L-histidine(N,N-di-n-hexadecylamin-
e)ethylamide) were added before removing Triton
X-100.7
FPL-Mediated Transfection of Cultured Cells.
Gunn rat hepatocytes (isolated by collagenase perfusion
of the liver), Hepa-1, an ASGPR-positive mouse hepa-
toma cell line, and ASGPR-negative 293 cells were incu-
bated with FPL loaded with pT2-pCAAGS-LacZ//eIF-
SB10 or pT2-pCAAGS-hUGT1A1//eIF-SB10 (2-4 g /
2 mL of serum-free medium) for 2 hours. E. coli -galac-
tosidase activity was determined by cytochemical staining
and hUGT1A1 expression was evaluated by immunocy-
tochemical staining using a monoclonal antibody,
WP1.13
Gene Transfer In Vivo. For short-term tissue distri-
bution studies we injected FPL, loaded with pT2-
pCAAGS-Luc//eIF-SB10 (4 g DNA in 0.25 mL by tail
vein injection over 2 minutes) into four Gunn rats. The
rats were killed 72 hours later and liver, kidney, spleen,
brain, and lungs were harvested for determination of lu-
ciferase activity.14 For long-termmetabolic studies, Gunn
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rats underwent tail vein injection with pT2-pCAAGS-
hUGT1A1//eIF-SB10 (4 g or 8 g/day for 4 days) en-
trapped in FPL with or without histidine lipid. For
comparison, the rats were injected saline or the naked
DNA (8 g). Serum bilirubin levels were measured at
various timepoints. After 28 weeks, bile samples were col-
lected by bile duct cannulation for bile pigment analysis
by high pressure liquid chromatography.15 The rats were
then sacrificed and tissues were harvested to determine the
biodistribution of the transgene polymerase chain reac-
tion (PCR) amplification of total DNA. Hepatic
hUGT1A1 expression was determined byWestern blot of
liver homogenates and immunohistochemical staining of
paraffin sections using WP1. UGT1A1 activity with bil-
irubin was determined as described.16
Transposition Site Analysis. Transposition sites were
recovered by two-step inverted PCR amplification of ligated
chromosomal DNA.17 Chromosomal sequences flanking
the insertion sites were matched with the rat genomic se-
quence data base to determine the insertion sites.
Evaluation of HSB3 Coding Sequence Persistence.
Total liver DNA from saline-treated control or treated
Gunn rats was subjected to PCR amplification to deter-
mine if the coding sequence the HSB3 transposase per-
sisted in the livers of the treated animals.
Evaluation of Humoral Immune Response to F-
Protein or hUGT1A1. Using whole Sendai virus pro-
teins or hUGT1A1 expressed in Gunn rat fibroblasts as
antigen, we evaluated the presence of antibodies in the
sera of treated Gunn rats by Western blotting. As positive
controls, we used an anti-Sendai virus polyclonal anti-
body or WP1, respectively.
Histological Examination of the Liver. Paraffin-
embedded liver sections were examined by hematoxylin-
eosin staining to evaluate morphological injury or cellular
infiltration.
Serum Alanine Aminotransferase (ALT) and Albu-
min Analysis. These measurements were performed to
evaluate liver injury and synthetic function after treat-
ment.
Statistical Analysis. Serum bilirubin levels at various
timepoints after treatment were compared with those of
control groups by Student’s t test. P-values  0.01 were
considered significant.
Fig. 1. cis pT2-pCAAGS-hUGT1A1//eIF-SB10 plasmid construct expressing both human UGT1A1 and a hyperactive SB transposase (HSB3):
human UGT1A1 is expressed from the hybrid SV40 enhancer-human elongation factor 1 (SV40EF1) promoter and HSB3 is expressed from the
mammalian intrinsic factor A1 (mIFA1) promoter. The UGT1A1 transcription unit, consisting of the promoter-enhancer, coding region, untranslated
3LTR, and the SV40 polyadenylation signal (SV40 poly(A)) is flanked by the IR/DR that are substrates of HSB3. ColE1 Ori, E. coli site of origin;
Kan(R), kanamycin resistance gene.
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Results
FPL-Mediated Gene Transfer into Cultured Cells
Depended on the Presence of ASGPR. To determine
whether FPL-mediated gene transfer required cell-surface
ASGPR, we transfected Hepa1 cells (an ASGPR mouse
hepatoma cell line) or 293 cells (an ASGPR human kid-
ney epithelial cell line) with a plasmid expressing E. coli
-galactosidase (pT2-pCAAGS-LacZ//eIF-SB10). Ten
to 20% of transfected Hepa1 cells exhibited the expres-
sion of bacterial -galactosidase, whereas there was no
expression of the marker gene in 293 cells (Fig. 2A-C).
Next, we evaluated the ability of FPL to transfer the
plasmid expressing human UGT1A1 (pT2-pCAAGS-
hUGT1A1//eIF-SB10) into primary Gunn rat hepato-
cytes. Immunocytochemical staining showed that 15%-
22% of the hepatocytes expressed human UGT1A1 after
transfection (Fig. 2D,E).
Intravenous Injection of FPL-DNA Results in
Transgene Expression Exclusively in the Liver. To
determine short-term tissue distribution of transgene ex-
pression, FPL loaded with the plasmid expressing firefly
luciferase (pT2-pCAAGS-Luc//eIF-SB10, 4 g DNA)
was injected intravenously. Three days after injection, lu-
ciferase activity was detected in the liver (1,200,000
RLU/mg tissue) but not in the kidney, spleen, brain, and
lungs. When the firefly luciferase gene was injected with-
out entrapment in FPL, no luciferase activity above the
background (noise) was detectable in the liver or any
other tissue, 72 hours after the injection.
Integration of the hUGT1A1 Transgene into the
Genomic DNA of Gunn Rat Liver. To determine
whether the expression of the hUGT1A1 was from inte-
grated transgene or from episomally carried copies of the
SB-Tn, total liver DNA was PCR-amplified to determine
the presence of the HSB coding sequence. No amplifica-
tion products were found in treated Gunn rats (Fig. 3A).
In contrast, when liver DNA from an untreated Gunn rat
was spiked with15 ng of plasmid containing the HSB3
CDS, an amplicon of the predicted size (136 base pairs
[bp]) was readily detectable. Using 2 g of the isolated
liver DNA from the treated and control Gunn rats as
template, inverted nested PCR was used to recover
genomic insertion sites. Four sequences were retrieved,
one located within an intron of a Reference Sequence-
identified gene RGD1310066 and the location of the
other three were not identified using the megablast search
against the existing genomic rat data base. This may be
explained by the Gunn rat being on a Wistar-RHA (Ro-
man high avoidance) background, whereas the rat
genomic sequences compiled to date are from outbred
Harlan-Sprague Dawley rats. Moreover, intergenic re-
gions of the rat genome have not been completely se-
quenced and may also contribute to the lack of genomic
assignment as 2/3 of SB-mediated insertions occur in
nontranscribed regions of the genome. Together, the re-
sults indicated that, whereas the hUGT1A1 transcription
units are integrated into the rat genome, the SB coding
region is lost as a result of the transposase activity, which
cleaves the transposon plasmid, at the IR/DR sequences,
resulting in its degradation.
Long-Term Studies In Vivo. In initial studies we
tested the dose response by injecting 2 to 32 g of FPL-
entrapped pT2-pCAAGS-hUGT1A1//eIF-SB10 into
Gunn rat tail veins. Two weeks later, Western blot anal-
ysis of the liver showed a maximum hUGT1A1 expres-
Fig. 2. Transfection of cultured cells with FPL loaded with plasmid DNAs. (A-C) transfected cell stained for E. coli -galactosidase expression. (A)
Hepa1 cells, untransfected; (B) Hepa1 cells transfection with FPL loaded with pT2-pCAAGS-LacZ//eIF-SB10; (C) 293 cells transfected with FPL loaded
with pCMV-LacZ. (D,E) Immunocytochemical staining for human UGT1A1. (D) Primary Gunn rat hepatocytes, untransfected; (E) primary Gunn rat
hepatocytes, transfected with FPL loaded with pT2-pCAAGS-hUGT1A1//eIF-SB10.
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sion at the 8 g dose, above which the signal did not
increase. Thereafter, we injected 4 g FPL-entrapped
DNA daily for 1, 2, 3, or 4 days, which showed a progres-
sive increase in the Western blot signal intensity. For ini-
tial determination of the effect of incorporating histidine
lipid into FPL, we gave Gunn rats four daily injections of
4 g of pT2-pCAAGS-hUGT1A1//eIF-SB10 entrapped
into FPL with or without histidine lipid. After 14 days,
Western blot of the liver homogenates showed a 40%-
50% increase in hUGT1A1 expression when histidine
lipid was incorporated into FPL (Supporting Fig. 2).
Therefore, in subsequent long-term experiments we used
daily injection of 4 g or 8 g DNA for 4 days. Five
groups of Gunn rats, each consisting of six rats, received
daily injections for 4 days as follows: (1) Age-matched
controls receiving intravenous saline, (2) 4 g DNA in
FPL without histidine lipid, (3) 4 g DNA in FPL with
histidine lipid, (4) 8g DNA in FPL with histidine lipid,
(5) 8g naked DNAwithout FPL. Serum bilirubin levels
were followed for 28 weeks, when the bile was collected
for bile pigment analysis and the rats were sacrificed. Tis-
sues were analyzed by DNA PCR, Western blot, liver
histology and immunohistochemical staining, and
UGT1A1 assay as described below.
Liver-Specific Persistence of the Transposition-Com-
petent Transgene Delivered by FPL. Human UGT1A1
coding sequences were amplified by PCR from total DNA
extracted from various tissues 28 weeks after injections of
FPL-entrapped pT2-pCAAGS-hUGT1A1//eIF-SB10 once
daily for 4 days. As shown in Fig. 4A, DNA extracted from
the livers, but not lungs, kidney, and spleen, yielded ampli-
cons of the expected size.
Western Blot Analysis. Twenty-eight weeks after
treatment, expression of human UGT1A1 was demon-
strated in liver homogenates of the Gunn rats (Fig. 4B).
The 52 kiloDalton (kDa) transgene product comigrated
with human UGT1A1 expressed in stably transduced
Gunn rat fibroblasts.18 As expected, saline-treated Gunn
rat livers did not show any immunoreactive bands. To
evaluate the requirement of the SB transposase in the
Fig. 3. Sleeping Beauty-mediated genomic insertion. (A) Total liver DNA isolated from Gunn rats was subjected to PCR to detect the presence of
HSB3 coding sequences. C, control untreated Gunn rat DNA spiked with the pT2-pCAAGS-hUGT1A1//eIF-SB10 plasmid. Amplification of the plasmid
yielded the expected 136 bp amplicon. M, DNA ladder in 100-bp increments. Positions of the 300 bp and 100 bp markers are indicated. Lane 1,
water control; lane 2, untreated Gunn rat; lanes 3 and 4, livers from two Gunn rats treated with four daily intravenous injections of pT2-pCAAGS-
hUGT1A1//eIF-SB10 (4 g DNA per dose). (B) Insertion sites determined by inverted nested PCR using the genomic DNA isolated from the treated
animals. The first 10 nucleotides of the IR/DR are shown with the bold gray TA being the duplicated TA genomic dinucleotide. The first 40 nucleotides
of the flanking genomic sequence is shown with the location determined by megablast against the National Center for Biotechnology Information
(NCBI) rat genome assembly indicated at far right. Ud, genomic location using megablast search on rat genome sequence did not provide a location.
*Located in the intron of RGD1310066 reference sequence gene on chromosome 7.
Fig. 4. Tissue distribution of human UGT1A1 transgene and its ex-
pression. Gunn rats were given intravenous injections of FPL loaded with
pT2-pCAAGS-hUGT1A1//eIF-SB10 (4 g DNA) or saline (control) once a
day for four doses as described in Materials and Methods. The recipients
were sacrificed after 28 weeks and tissues were harvested. (A) PCR
amplification of DNA extracted from various tissues. The data represent
results from individual mice representative of the various experimental
groups. Lane 1, molecular weight markers; lane 2, lungs; lane 3, kidney;
lane 4, spleen; lane 5, brain; lane 6, testis; lanes, 7-12, DNA from livers
of six different Gunn rats treated with FPL loaded with 4 g of pT2-
pCAAGS-hUGT1A1//eIF-SB10; lane 13, pT2-pCAAGS-hUGT1A1//eIF-
SB10; lane 14, liver from saline injected control. (B) Western blot
analysis of human UGT1A1 expression. Lanes 1-6, Gunn rats treated with
FPL loaded with pT2-pCAAGS-hUGT1A1//eIF-SB10: lanes 1-3, 4 g
DNA; lanes 4-6, 8 g DNA; lanes 7 and 8, untreated Gunn rat liver; lane
9, Gunn rat skin fibroblast, stably transfected with human UGT1A1. (C)
Immunofluorescent staining of liver cryostat sections. 1, Untreated Gunn
rat; 2, a Gunn rat treated with FPL loaded with pT2-pCAAGS-hUGT1A1//
eIF-SB10 (4 g DNA). The DAPI-stained nuclei exhibit blue fluorescence,
whereas human UGT1A1 exhibits red fluorescence.
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persistence of transgene expression, we injected an FPL-
entrapped plasmid expressing hUGT1A1, but not HSB
(pT2-pCAAGS-hUGT1A1) (8 g DNA/day for 4 days).
Western blot of liver homogenates showed the expression
of hUGT1A1 1 week after the injections, but not the
28-week time point (data not shown in Fig. 4B).
Immunohistochemistry. Immunofluorescent stain-
ing of frozen liver sections showed hUGT1A1 expression
in livers of Gunn rats treated with FPL-entrapped pT2-
pCAAGS-hUGT1A1//eIF-SB10, but not in the saline-
treated age-matched controls (Fig. 4C, left panel).
Clumpy cytoplasmic distribution and linear distribution
in the nuclear envelope were consistent with the endo-
plasmic reticulum localization of UGT1A1 (Fig. 4C,
right panel).19
UGT1A1 Activity Toward Bilirubin. UGT1A1 ac-
tivity toward bilirubin in liver homogenates from wild-
type Wistar-RHA rats (congeneic with the Gunn rats
used in this study) was 2.2 0.4 mol/g wet weight per
hour. As expected, there was no detectable UGT1A1 ac-
tivity in the livers of saline-treated control Gunn rats.
Twenty-eight weeks after injections of FPL-pT2-
pCAAGS-hUGT1A1//eIF-SB10 inGunn rats, UGT1A1
activity in the liver homogenates of the recipients was
0.31 0.11 mol/g wet weight per hour.
Serum Bilirubin Levels. As serum bilirubin levels
change with age in Gunn rats, we expressed serum biliru-
bin concentrations both as percentage of the levels in age-
matched controls (Fig. 5A) and in absolute values (Fig.
5B). After four injections 4 g of pT2-pCAAGS-
hUGT1A1//eIF-SB10 entrapped in FPL without histi-
dine lipid, serum bilirubin levels declined slowly to
75%of the levels in saline-treated age-matched controls
in 8 weeks (P  0.01) (Fig. 5A,B). Reduction of serum
bilirubin was more pronounced when histidine lipid was
incorporated in the FPL bilayer, so that serum bilirubin
Fig. 5. Metabolic effect of FPL-mediated gene transfer. (A) Serum bilirubin levels relative to age-matched controls. Gunn rats were given daily
intravenous injections of FPL loaded with pT2-pCAAGS-hUGT1A1//eIF-SB10 for 4 days or saline (untreated control). (A) Serum bilirubin levels are
shown as percent of mean bilirubin concentration in age-matched, saline-treated controls. Values are means  standard deviation; n  6 in each
group. Mean values for the group receiving 4 g plasmid DNA per dose in FPL without histidine lipid (open circles) were significantly lower (P 
0.01) than in age-matched controls from the 8-week timepoint onward. In groups receiving either 4 g (triangles) or 8 g DNA (solid diamonds)
per dose in FPL containing histidine lipids the mean values were significantly lower (P  0.01) than in controls at all time 4 weeks and beyond.
In contrast, injection of the plasmid without incorporation into FPL did not result in significant change in mean serum bilirubin levels (open diamond,
P  0.5). (B) The experimental groups are identical to those in (A), but serum bilirubin levels shown as absolute concentrations. 1, untreated
age-matched controls; 2, 4 g plasmid DNA per dose in FPL without histidine lipid; 3, 4 g DNA per dose in FPL containing histidine lipids; 4, 8
g DNA per dose in FPL containing histidine lipids; 5, 8 g naked DNA per dose without FPL. Asterisks indicate values that are significantly lower
(P  0.01) than in age-matched controls. (C) High-pressure liquid chromatographic analysis of pigments excreted in bile. A single representative
sample from the control (saline-treated) group (n 6), the treated group that received FPL with histidine lipid plus pT2-pCAAGS-hUGT1A1//eIF-SB10
(4 g) (n  6) and a congeneic wild-type Wistar-RHA rat are shown.
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levels were significantly lower at all timepoints beyond 2
weeks, and stabilized at 42% to 50% below the control
levels (P  0.01). Mean serum bilirubin levels in the
group receiving 8 g DNA/day entrapped in FPL con-
taining histidine lipids were slightly lower than those in
the 4g DNA/day group at timepoints after 8 weeks, but
the difference was not statistically significant.When pT2-
pCAAGS-hUGT1A1//eIF-SB10 was administered with-
out FPL, there was no significant reduction of serum
bilirubin at any timepoint, indicating the effectiveness of
FPL in gene delivery (Fig. 5A,B).
Excretion of Bilirubin Glucuronides in Bile. Chro-
matographic analysis of bile pigments from control Gunn
rats showed no bilirubin glucuronides and unconjugated
bilirubin (UCB) was the major peak (Fig. 5A), whereas
bile of Gunn rats that had received injections of FPL-
entrapped pT2-pCAAGS-hUGT1A1//eIF-SB10 con-
tained both bilirubin diglucuronide (BDG) and bilirubin
monoglucuronide (BMG), in addition to a small amount
of UCB (Fig. 5B). BDG and BMG were the major pig-
ments in bile from wildtype Wistar-RHA rats (Fig. 5C).
Serum Albumin and ALT Levels. Serum albumin
and ALT levels were determined before injections and 1,
2, 4, 8, and 28 weeks after the series of FPL-DNA injec-
tions to evaluate hepatic protein synthetic function and
liver injury, respectively. Serum albumin levels remained
between 3.8 and 4.3 g/dL in both control and treated
groups, and serum ALT levels remained between 35 and
45 IU. At no time was there a significant difference be-
tween the values in the control and the treated groups.
Evaluation of Humoral Immune Response Against
FPL and Human UGT1A1. Western blot analysis was
performed to determine whether there was an antibody
response in the treated Gunn rats against the F-protein or
human UGT1A1. Sera from FPL-treated rats did not
yield a positive band against the F-protein at the range of
dilutions tested (Fig. 6A, lanes 1-3). An immunoreactive
band of expected size for the F-protein was observed when
a rabbit anti-Sendai virus envelope antiserum was used
(positive control, Fig. 6A, lane 4).
Sera from the treated Gunn rats did not yield an im-
munoreactive band against humanUGT1A1 expressed in
Gunn rat fibroblasts (Fig. 6B, lanes 1-3). In contrast, sera
from rats treated with a lentiviral vector expressing human
UGT1A1 from the ubiquitous PGK promoter showed a
single immunoreactive band of the size expected for hu-
man UGT1A1 (Fig. 6B, lane 4).
Histological Examination of the Liver. Hematoxy-
lin-eosin staining of liver sections from the treated and
control Gunn rats showed completely normal architec-
ture and cellular morphology. There was no evidence of
infiltration by inflammatory cells and no increase in the
number of apoptotic bodies (Fig. 6C,D).
Discussion
We have shown efficient transgene integration specifi-
cally into the genome of hepatocytes, mediated by nonvi-
ral systemic delivery. To our knowledge, this is the first
report of long-term amelioration of a liver-based meta-
bolic disease by intravenous administration of a plasmid
entrapped in liposomes. The success of this strategy de-
pended on two components of the gene transfer system.
FPL permitted gene delivery targeted to hepatocytes after
systemic administration, which may explain the observed
lack of host immune response toward the gene delivery
Fig. 6. Evaluation of antibody response and liver histology. (A) West-
ern blot using sera from recipient Gunn rats against proteins of the
Sendai virus envelope. Gunn rats were injected with FPL loaded with
pT2-pCAAGS-hUGT1A1//eIF-SB10 once a day for 4 days (lanes 1 and 2,
4 g DNA daily; lane 3, 8 g DNA daily). Sera were collected 28 weeks
after the injections. Western blot analysis was performed against Sendai
virus envelope proteins resolved by sodium dodecyl sulfate-polyacrylam-
ide gel electrophoresis (SDS-PAGE). Various dilutions of the sera were
tested. The figure shows results with 1:400 dilution. Lane 4, serum from
a Gunn rat, which had been injected with both HN and F protein of the
Sendai virus envelope, prepared as described in the text. Lane 5, Sendai
virus envelope proteins were resolved by SDS-PAGE and proteins were
visualized by Coomassie blue staining. HN, hemagglutinin; F1 and F2, the
two subunits of the F-protein. (B) Western blot using sera from recipient
Gunn rats against human UGT1A1. Gunn rats were treated as in (A). The
sera were tested by Western blots against an extract of Gunn rat skin
fibroblasts stably transduced with human UGT1A1. Lanes 1-3 are from
rats as in the corresponding lanes in (A); lane 4, serum from a Gunn rat
that was injected a lentiviral vector expressing human UGT1A1; and lane
5, a monoclonal antibody that recognizes human UGT1A isoforms at a
1:4,000 dilution. (C) Hematoxylin-eosin stained paraffin-embedded liver
section from a Gunn rat 7 days after four injections of FPL loaded with
pT2-pCAAGS-hUGT1A1//eIF-SB10 (8 g). (D) Liver section 28 weeks
after the injection.
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vehicle and the transgene product. The second compo-
nent was the plasmid construct, which was engineered to
coexpress a hyperactive SB transposase that promoted in-
tegration of the human UGT1A1 into the host genome.
For hepatocyte-specific gene delivery, we generated li-
posomes with a single glycoprotein, F, derived from the
Sendai virus envelope, incorporated in the lipid bilayer.
Other investigators have demonstrated that efficient gene
transfer can be achieved in vitro and in vivo using lipo-
somes containing both of the two major proteins of the
Sendai virus, HN and F.8 However, in the presence of
HN the F-protein binds ubiquitously to all cell types,
which is a potential source for toxicity and immunogenic-
ity against the proteins contained in the gene transfer
vehicle, as well as the transgene product, which may be
recognized as a foreign protein in the recipient. We re-
ported previously that in the absence of HN the F-protein
loses its ubiquitous cell surface binding property and its
binding becomes dependent on the interaction of its car-
bohydrate component to ASGPR, which is expressed spe-
cifically on the hepatocyte cell surface.6
The fusogenic property of the F-protein is partly re-
tained after removal of HN, so that following binding to
ASGPR-positive cells, the contents of the liposome are
deposited directly into the cytosol, bypassing the classical
endocytotic pathway that directs the ligand to lysosomes.
However, the full complement of fusogenic activity of the
F-protein requires interaction with histidine groups of
HN. Therefore, incorporation of histidine lipids in the
FPL increases the fusogenic activity and macromolecule
transferring ability of FPL.7,20 Based on these observa-
tions, we hypothesized that FPL-loaded transgenes would
be delivered and expressed specifically in hepatocytes in
vitro and in vivo. In a cell culture system, ASGPR
Hepa-1 cells but not ASGPR 293 cells expressed the
transgene after FPL-mediated delivery of a plasmid ex-
pressing human UGT1A1, which was consistent with the
requirement of ASGPR for gene transfer.
To examine whether transgenes delivered in vivo by
way of systemic administration of FPL are expressed spe-
cifically in the liver, we performed both short-term and
long-term studies. In both cases we used ubiquitous pro-
moters to avoid transcription restriction of transgene ex-
pression. Three days after FPL-mediated administration
of a luciferase-expressing plasmid, luciferase activity was
detectable in the liver, but not in the other tissues tested.
Similarly, in long-term experiments, 28 weeks after gene
transfer, the transgene was detectable by PCR only in the
liver. Consistent with our previous observation that histi-
dine lipids increased its fusogenic activity of the F-pro-
tein,6 there was a more pronounced hypobilirubinemic
response when histidine lipids were incorporated in the
FPL. The liver-specificity of transgene delivery after intra-
venous injection of FPL was in sharp contrast to the re-
ported results using liposomes containing both HN and
F, which resulted in transgene expression mainly in the
spleen, but not in the liver.8 For gene delivery to the liver,
other investigators have used “hydrodynamic” injection,
which consists of very rapid intravenous injection of the
DNA in a large volume (1.5 	 blood volume) to cause
transient cardiac failure and consequent hepatic conges-
tion resulting in gene transfer.21 Using FPL, we obtained
comparable levels of hepatic transgene expression using
one-hundredth the dose of DNA and at an injection vol-
ume, which has no hemodynamic consequence. There-
fore, in terms of clinical translatability, FPL is superior to
existing methods of liver targeted gene delivery by sys-
temic administration.
Our second hypothesis was that the highly efficient
ASGPR-mediated internalization of FPL and its DNA
cargo by hepatocytes would minimize the exposure of the
F-protein and the transgene product (human UGT1A1)
to antigen-presenting cells, thereby circumventing host
immune response. This is relevant to gene therapy in gen-
eral because the lack of immune response would permit
repeated administration of the vehicle-DNA complex and
would spare the recipient tissues from immune-mediated
injury. In addition, in many cases of inherited metabolic
diseases, the mutant had never been exposed to the miss-
ing protein. Therefore, the therapeutic gene product may
be treated as a foreign protein, resulting in host immune
response. Expression of humanUGT1A1 inGunn rats by
systemic administration of lentiviral vectors has been re-
ported to result in the development of anti-human
UGT1A1 antibodies and coincident reduction of hepatic
UGT1A1 activity.22 Here we have confirmed the devel-
opment of antibodies against human UGT1A1 after len-
tiviral gene transfer in Gunn rats. In contrast, FPL-
mediated expression of humanUGT1A1 did not result in
an antibody response. Although we did not directly exam-
ine cell-mediated immune response against the transgene-
expressing cells, normal morphology of the hepatocytes,
the lack of infiltration by inflammatory cells, and the ab-
sence of transaminase elevation indicate the absence of
any cell-mediated immune reaction. For both the lentivi-
ral vector and our transposition-competent plasmid, hu-
man UGT1A1, expression was driven by a ubiquitous
promoter, so that there was no translational restriction to
specific tissues. This suggests that the lack of immune
response in the case of FPL-mediated gene transfer was
due to restriction of gene delivery to hepatocytes, which is
consistent with our finding of liver-specific distribution of
hUGT1A1 sequences.
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As inherited metabolic disorders are lifelong condi-
tions, gene therapy for these conditions may be facilitated
by integration of the transgene into the host genome, so
that the gene would be transmitted to the progeny of the
transduced cells after mitosis. The plasmid utilized in our
study expresses the SB transposase and human UGT1A1
from two different transcription units. The transcription
unit expressing human UGT1A1 is flanked by IR/DR
DNA sequences that are substrates for the transposase.
When the SB transposase is expressed, it catalyzes the
excision of the DNA segment located between the IR/
DRs, followed by insertion of DNA segment at AT dinu-
cleotide sites in the cellular chromosomes. The
mechanism and characteristics of SB-mediated gene tran-
scription have been described.10,11 In this study we used a
partially sequence modified version of SB, which was gen-
erated by Yant and associates and was reported to be more
efficient in mediating DNA transposition than previous
versions of the enzyme. Notably, excision of the target
DNA unit by the transposase results in cleavage and de-
struction of the plasmid, minimizing the chance of re-
peated transposition. We determined the flanking
genomic sequence at several sites of insertion of the
hUGT1A1 transcription units in the rat genome by in-
verse PCR. The presence of the TA dinucleotides at the
insertion sites provided evidence that the integration was
mediated by SB transposase. Because the map of rat ge-
nome is not as complete as the human or mouse genome,
we were able to identify the location of the integrations on
rat chromosomes in some but not all cases.
In summary, intravenous injection of FPL, loadedwith
a therapeutic plasmid, resulted in liver-specific delivery
and expression of the transgene. In vivo transduction of
hepatocytes was efficient enough to achieve reduction of
hyperbilirubinemia in the Gunn rat model of CN-1. The
SB transposition system enabled integration of the thera-
peutic gene into the host genome, permitting long-term
metabolic effect. FPL-based gene delivery obviates the use
of recombinant viral vectors and did not result in an im-
mune response and detectable toxic effect. SB-mediated
transposition sites are scattered throughout the genome,
without preference to sites close to expressed genes. This
reduces the probability of insertional mutagenesis. Several
laboratories are engaged in engineering additional safety
features, such as inserting insulator sequences flanking the
transcription units to prevent accidental activation of pro-
moters of neighboring genes23 and addingDNA targeting
elements to the transposase to promote site-preference of
integration.24,25 Clinical trials are being proposed for gene
therapy based on the SB transposition system.26 Further-
more, liver-targeted delivery of a plasmid expressing a
short-hairpin RNA directed against the internal ribo-
somal entry site (IRES) of the hepatitis C virus resulted in
selective inhibition ofHCV IRES-mediated translation.27
Thus, our combined strategy of FPL-based hepatocytes
targeted delivery of transposition competent DNA has
the potential to be developed for gene therapy for inher-
ited liver-based metabolic disorders.
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